MSLN and neoplasm: Currently, various mesothelin-targeted therapeutic strategies, including anti-mesothelin antibodies, antibody-drug conjugates (ADC), and Chimeric Antigen Receptor T-cell Therapy (CAR-T), have demonstrated promising anti-tumor efficacy in preclinical studies and some early-stage clinical trials.